Neuron23

Biotech · Private

LRRK2 kinase inhibitor small molecule therapeutic (NE-021) for Parkinson's disease

neuron23.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
34
0 granted · 34 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2006Dispatch Biotherapeutics——
2007OROX BIOSCIENCES, INC.——
2008cAMPfield Therapeutics——
2009Neuron23——
2010AlloTRx Bio Inc.—$500K
2011DEGRANIN THERAPEUTICS, LLC——
2012ashibio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 34
  • Predictive Biomarkers And Use Thereof To Treat Parkinson's Diseaseapplication
  • LRRK2 Inhibitors And Uses Thereofapplication
  • LRRK2 Inhibitors And Uses Thereofapplication
  • Kinase Modulators And Methods Of Use Thereofapplication
  • Kinase Modulators And Methods Of Use Thereofapplication
  • Methods Of Treatment And Diagnosis Of Parkinson's Disease Associated With Wild-type LRRK2application
  • Kinase Modulators And Methods Of Use Thereofapplication
  • LRRK2 Inhibitors And Uses Thereofapplication
  • LRRK2 Inhibitors And Uses Thereofapplication
  • Kinase Modulators And Methods Of Use Thereofapplication
  • LRRK2 Inhibitors And Uses Thereofapplication
  • Predictive Biomarkers And Use Thereof To Treat Parkinson's Diseaseapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.